Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
125 shown of 6,789 total abstracts
  1. Abstract 97652026-06-05 · 20:15 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-137 study)
    G. Curigliano, S. Modi, H. Borghaei, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  2. Abstract 96462026-06-02 · 13:45 CT · S100A
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-699
    G. Curigliano, P. Schmid, S. Peters · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  3. Abstract 94892026-06-04 · 16:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-988 study)
    F. Andre, S. Tolaney, C. Saura, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  4. Abstract 99112026-06-05 · 14:00 CT · S100A
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    M. Reck, S. Tolaney, E. Winer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  5. Abstract 99862026-06-02 · 18:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-270 study)
    M. Reck, J. Cortes, M. Krop, et al. · Mayo Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  6. Abstract 94022026-06-03 · 14:30 CT · Arie Crown Theater
    Quality of life outcomes with Imfinzi in patients with SCLC
    C. Robert, M.C. Garassino, M. Reck, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  7. Abstract 97692026-06-01 · 19:00 CT · E450
    FLAURA-98: Tagrisso (osimertinib) 3L+ in NSCLC
    M.C. Garassino, H. Rugo, H. Borghaei · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  8. Abstract 96492026-06-02 · 20:30 CT · E450
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-586
    S. Modi, M.C. Garassino · Royal Marsden Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  9. Abstract 92372026-06-01 · 16:15 CT · S406
    Long-term follow-up of Enhertu 2L for NSCLC: DESTINY-Breast-713
    M. Krop, S. Peters, G. Curigliano · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  10. Abstract 96702026-06-03 · 14:45 CT · S100A
    DESTINY-Breast-51: Enhertu (trastuzumab deruxtecan) 1L in NSCLC
    C. Robert, L. Paz-Ares, C. Saura, et al. · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  11. Abstract 92892026-06-04 · 14:30 CT · S100A
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    F. Andre, E. Winer · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  12. Abstract 92092026-06-05 · 16:15 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-214 study)
    F. Andre, M. Krop, A. Spira, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  13. Abstract 98242026-06-04 · 14:15 CT · S100A
    Quality of life outcomes with Keytruda in patients with NSCLC
    N. Rizvi, L. Paz-Ares · Princess Margaret Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  14. Abstract 94052026-06-05 · 16:15 CT · E450
    FLAURA-631: Tagrisso (osimertinib) 2L in NSCLC
    E. Winer, R. Herbst · Institut Gustave Roussy
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  15. Abstract 91112026-06-05 · 21:00 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-525
    E. Winer, R. Herbst, M. Krop, et al. · MD Anderson Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  16. Abstract 98322026-06-04 · 19:45 CT · S406
    Real-world effectiveness of Opdivo vs standard of care in NSCLC
    S. Antonia, G. Curigliano · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  17. Abstract 96772026-06-01 · 15:45 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-262 study)
    S. Modi, S. Peters · Princess Margaret Cancer Centre
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  18. Abstract 98932026-06-04 · 16:30 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-818
    S. Antonia, J. Cortes, A. Spira · Institut Gustave Roussy
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  19. Abstract 90672026-06-02 · 16:30 CT · Arie Crown Theater
    Quality of life outcomes with Enhertu in patients with NSCLC
    H. Borghaei, L. Paz-Ares, A. Spira, et al. · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  20. Abstract 93512026-06-03 · 19:30 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-639
    S. Modi, M.C. Garassino, C. Robert, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  21. Abstract 94892026-06-01 · 20:00 CT · S100A
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-680
    L. Paz-Ares, S. Modi · Princess Margaret Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  22. Abstract 99362026-06-01 · 20:30 CT · S406
    DESTINY-Breast-536: Enhertu (trastuzumab deruxtecan) 2L in NSCLC
    H. Borghaei, R. Herbst, G. Curigliano, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  23. Abstract 99902026-06-03 · 21:45 CT · E450
    FLAURA-275: Tagrisso (osimertinib) neoadjuvant in NSCLC
    H. Rugo, R. Herbst · Princess Margaret Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  24. Abstract 91252026-06-01 · 19:30 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-78 study)
    M. Krop, C. Robert, H. Rugo, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  25. Abstract 95352026-06-03 · 16:00 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-138
    H. Borghaei, C. Robert, M.C. Garassino, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  26. Abstract 92372026-06-04 · 21:15 CT · S406
    Real-world effectiveness of Tecentriq vs standard of care in NSCLC
    R. Herbst, H. Rugo, S. Peters, et al. · University of Chicago
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  27. Abstract 91612026-06-03 · 14:30 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-119 study)
    M.C. Garassino, S. Tolaney, R. Herbst · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  28. Abstract 93482026-06-05 · 21:15 CT · Arie Crown Theater
    KEYNOTE-757: Keytruda (pembrolizumab) neoadjuvant in NSCLC
    H. Rugo, T. Mok, R. Herbst · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  29. Abstract 93262026-06-03 · 13:00 CT · E450
    Real-world effectiveness of Imfinzi vs standard of care in NSCLC
    L. Paz-Ares, S. Modi, G. Curigliano, et al. · University of Chicago
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  30. Abstract 90042026-06-03 · 21:45 CT · E450
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-930
    G. Curigliano, M. Reck, F. Andre, et al. · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  31. Abstract 93522026-06-01 · 13:15 CT · S100A
    Long-term follow-up of Tecentriq maintenance for NSCLC: IMpower-239
    C. Robert, R. Herbst · Institut Gustave Roussy
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  32. Abstract 90892026-06-04 · 14:30 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with SCLC
    S. Peters, L. Paz-Ares · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  33. Abstract 99212026-06-04 · 16:30 CT · Hall B1
    Quality of life outcomes with Tagrisso in patients with NSCLC
    C. Robert, G. Curigliano, A. Spira, et al. · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  34. Abstract 96492026-06-04 · 21:15 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-860
    G. Curigliano, M. Reck, P. Schmid · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  35. Abstract 92382026-06-04 · 16:15 CT · S406
    Real-world effectiveness of Keytruda vs standard of care in NSCLC
    R. Herbst, H. Rugo, M.C. Garassino · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  36. Abstract 90902026-06-02 · 20:45 CT · S406
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-813
    C. Robert, J. Cortes, S. Antonia, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  37. Abstract 95782026-06-05 · 13:15 CT · S100A
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-917
    J. Brahmer, P. Schmid, S. Tolaney · MD Anderson Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  38. Abstract 94842026-06-05 · 16:15 CT · E450
    PACIFIC-105: Imfinzi (durvalumab) 1L in NSCLC
    G. Curigliano, R. Herbst, T. Mok, et al. · Cleveland Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  39. Abstract 99412026-06-04 · 13:30 CT · E450
    KEYNOTE-356: Keytruda (pembrolizumab) 3L+ in NSCLC
    T. Mok, S. Antonia · Princess Margaret Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  40. Abstract 95742026-06-04 · 19:30 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-237 study)
    J. Brahmer, S. Tolaney, A. Spira, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  41. Abstract 97732026-06-03 · 13:00 CT · S100A
    FLAURA-589: Tagrisso (osimertinib) 2L in NSCLC
    P. Schmid, M. Krop, R. Herbst, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  42. Abstract 99432026-06-02 · 16:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-199 study)
    H. Rugo, G. Curigliano, S. Tolaney · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  43. Abstract 90472026-06-05 · 13:00 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-620 study)
    M. Reck, F. Andre, H. Borghaei, et al. · Institut Gustave Roussy
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  44. Abstract 91222026-06-04 · 15:00 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-312 study)
    J. Brahmer, S. Antonia · University of Chicago
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  45. Abstract 92632026-06-04 · 15:30 CT · Hall B1
    Long-term follow-up of Keytruda adjuvant for SCLC: KEYNOTE-844
    J. Brahmer, M. Krop · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  46. Abstract 91162026-06-04 · 20:45 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-89 study)
    M. Krop, S. Peters, F. Andre, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  47. Abstract 90942026-06-04 · 19:30 CT · S100A
    Long-term follow-up of Imfinzi 1L for SCLC: PACIFIC-571
    S. Tolaney, S. Antonia, M. Krop · Princess Margaret Cancer Centre
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  48. Abstract 96192026-06-05 · 19:15 CT · Arie Crown Theater
    Long-term follow-up of Opdivo adjuvant for NSCLC: CheckMate-38
    N. Rizvi, S. Antonia · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  49. Abstract 97472026-06-04 · 20:45 CT · E450
    Quality of life outcomes with Imfinzi in patients with NSCLC
    F. Andre, C. Saura, M. Reck, et al. · Karolinska Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  50. Abstract 95072026-06-01 · 20:00 CT · E450
    Long-term follow-up of Enhertu maintenance for NSCLC: DESTINY-Breast-366
    P. Schmid, N. Rizvi, L. Paz-Ares · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  51. Abstract 96062026-06-04 · 14:00 CT · E450
    FLAURA-378: Tagrisso (osimertinib) maintenance in NSCLC
    T. Mok, P. Schmid, F. Andre, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  52. Abstract 98902026-06-01 · 13:45 CT · E450
    FLAURA-666: Tagrisso (osimertinib) 2L in NSCLC
    H. Rugo, A. Spira, S. Modi, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  53. Abstract 92562026-06-04 · 21:30 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-933
    N. Rizvi, H. Rugo · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  54. Abstract 95322026-06-03 · 13:30 CT · S406
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-422 study)
    H. Rugo, E. Winer, M.C. Garassino · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  55. Abstract 94412026-06-01 · 15:45 CT · E450
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-640 study)
    C. Robert, F. Andre, S. Modi, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  56. Abstract 97442026-06-02 · 18:45 CT · Arie Crown Theater
    PACIFIC-809: Imfinzi (durvalumab) 2L in NSCLC
    M. Krop, T. Mok · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  57. Abstract 98392026-06-01 · 18:45 CT · E450
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-932 study)
    M. Reck, A. Spira, N. Rizvi, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  58. Abstract 95902026-06-01 · 19:45 CT · S100A
    PACIFIC-571: Imfinzi (durvalumab) 1L in NSCLC
    S. Tolaney, J. Cortes · Stanford Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  59. Abstract 90142026-06-02 · 14:15 CT · Arie Crown Theater
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    F. Andre, H. Borghaei, E. Winer · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  60. Abstract 98392026-06-01 · 13:00 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-193
    M.C. Garassino, N. Rizvi, M. Krop, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  61. Abstract 90742026-06-04 · 19:00 CT · Arie Crown Theater
    FLAURA-907: Tagrisso (osimertinib) neoadjuvant in NSCLC
    J. Brahmer, S. Peters, J. Cortes · Stanford Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  62. Abstract 90992026-06-05 · 21:45 CT · S100A
    Real-world effectiveness of Keytruda vs standard of care in SCLC
    P. Schmid, J. Brahmer · Karolinska Institute
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  63. Abstract 90172026-06-03 · 19:45 CT · E450
    Long-term follow-up of Tecentriq 1L for NSCLC: IMpower-653
    S. Antonia, M. Krop, N. Rizvi, et al. · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  64. Abstract 98112026-06-03 · 18:00 CT · E450
    FLAURA-874: Tagrisso (osimertinib) 2L in NSCLC
    S. Modi, J. Brahmer, J. Cortes · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  65. Abstract 91242026-06-01 · 14:15 CT · Arie Crown Theater
    Quality of life outcomes with Opdivo in patients with NSCLC
    J. Brahmer, P. Schmid, T. Mok, et al. · Stanford Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  66. Abstract 93492026-06-04 · 13:00 CT · S100A
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-995 study)
    S. Peters, C. Saura, L. Paz-Ares · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  67. Abstract 99412026-06-03 · 21:30 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-191
    C. Saura, G. Curigliano · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  68. Abstract 97652026-06-01 · 15:15 CT · E450
    KEYNOTE-294: Keytruda (pembrolizumab) 1L in NSCLC
    H. Borghaei, H. Rugo, R. Herbst, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  69. Abstract 92592026-06-01 · 14:30 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-678 study)
    S. Antonia, R. Herbst, T. Mok, et al. · Mayo Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  70. Abstract 97042026-06-03 · 21:30 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-25 study)
    H. Rugo, J. Brahmer, F. Andre · Mayo Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  71. Abstract 96342026-06-01 · 21:30 CT · S406
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-135 study)
    M.C. Garassino, S. Tolaney, L. Paz-Ares, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  72. Abstract 93062026-06-03 · 19:15 CT · Arie Crown Theater
    Long-term follow-up of Enhertu 2L for NSCLC: DESTINY-Breast-248
    J. Cortes, S. Peters, J. Brahmer, et al. · Mayo Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  73. Abstract 97032026-06-02 · 14:30 CT · Hall B1
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-426
    S. Tolaney, E. Winer, C. Robert, et al. · Institut Gustave Roussy
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  74. Abstract 99272026-06-01 · 19:00 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-479 study)
    R. Herbst, M.C. Garassino, M. Krop · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  75. Abstract 90942026-06-03 · 14:45 CT · E450
    FLAURA-966: Tagrisso (osimertinib) neoadjuvant in NSCLC
    S. Tolaney, S. Modi · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  76. Abstract 96692026-06-04 · 18:30 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-17
    E. Winer, F. Andre, M. Krop · Stanford Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  77. Abstract 90462026-06-03 · 20:45 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-113
    C. Robert, M. Krop · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  78. Abstract 90512026-06-01 · 21:30 CT · E450
    FLAURA-637: Tagrisso (osimertinib) 2L in NSCLC
    M. Reck, S. Tolaney, E. Winer · MD Anderson Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  79. Abstract 92642026-06-05 · 21:30 CT · Hall B1
    CheckMate-833: Opdivo (nivolumab) maintenance in NSCLC
    S. Peters, N. Rizvi, T. Mok, et al. · Institut Gustave Roussy
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  80. Abstract 94212026-06-02 · 19:30 CT · E450
    CheckMate-96: Opdivo (nivolumab) 2L in NSCLC
    L. Paz-Ares, S. Tolaney, J. Cortes, et al. · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  81. Abstract 90082026-06-01 · 16:45 CT · E450
    Long-term follow-up of Keytruda 1L for SCLC: KEYNOTE-932
    G. Curigliano, H. Borghaei, S. Tolaney, et al. · Royal Marsden Hospital
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  82. Abstract 93152026-06-03 · 20:30 CT · Hall B1
    KEYNOTE-407: Keytruda (pembrolizumab) maintenance in NSCLC
    S. Peters, H. Rugo, N. Rizvi, et al. · Institut Gustave Roussy
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  83. Abstract 96722026-06-04 · 15:15 CT · E450
    FLAURA-406: Tagrisso (osimertinib) adjuvant in NSCLC
    M. Krop, A. Spira, C. Robert · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  84. Abstract 97052026-06-03 · 15:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-934 study)
    H. Rugo, G. Curigliano, C. Robert · University of Chicago
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  85. Abstract 96072026-06-03 · 14:30 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-418
    M. Krop, L. Paz-Ares, N. Rizvi · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  86. Abstract 93942026-06-04 · 14:15 CT · E450
    Long-term follow-up of Keytruda 1L for SCLC: KEYNOTE-607
    R. Herbst, S. Tolaney, A. Spira · Cleveland Clinic
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  87. Abstract 93002026-06-02 · 18:45 CT · E450
    KEYNOTE-239: Keytruda (pembrolizumab) maintenance in NSCLC
    G. Curigliano, S. Antonia, H. Borghaei · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  88. Abstract 91372026-06-04 · 15:45 CT · S100A
    Long-term follow-up of Imfinzi neoadjuvant for SCLC: PACIFIC-893
    H. Rugo, J. Brahmer · Royal Marsden Hospital
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  89. Abstract 95742026-06-02 · 21:45 CT · S100A
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-316 study)
    S. Antonia, S. Tolaney, F. Andre, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  90. Abstract 97602026-06-05 · 21:45 CT · Arie Crown Theater
    PACIFIC-983: Imfinzi (durvalumab) adjuvant in SCLC
    J. Brahmer, S. Peters · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  91. Abstract 94772026-06-03 · 21:30 CT · S406
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-860
    C. Saura, E. Winer · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  92. Abstract 95172026-06-02 · 16:15 CT · Hall B1
    KEYNOTE-193: Keytruda (pembrolizumab) 1L in SCLC
    S. Antonia, C. Saura, A. Spira, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  93. Abstract 92282026-06-02 · 14:45 CT · S100A
    IMpower-992: Tecentriq (atezolizumab) 3L+ in NSCLC
    S. Antonia, E. Winer, L. Paz-Ares, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  94. Abstract 99342026-06-03 · 19:45 CT · E450
    Long-term follow-up of Keytruda 1L for NSCLC: KEYNOTE-733
    S. Modi, J. Brahmer, N. Rizvi · Cleveland Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  95. Abstract 94092026-06-05 · 19:15 CT · Hall B1
    CheckMate-684: Opdivo (nivolumab) 1L in NSCLC
    S. Modi, S. Tolaney, N. Rizvi, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  96. Abstract 91602026-06-04 · 13:15 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-66 study)
    J. Cortes, C. Robert, S. Peters, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  97. Abstract 98872026-06-02 · 16:00 CT · Hall B1
    Long-term follow-up of Imfinzi adjuvant for NSCLC: PACIFIC-584
    A. Spira, J. Cortes, N. Rizvi, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  98. Abstract 91332026-06-04 · 15:15 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-951
    J. Brahmer, G. Curigliano, P. Schmid, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  99. Abstract 93932026-06-02 · 20:45 CT · S406
    DESTINY-Breast-584: Enhertu (trastuzumab deruxtecan) maintenance in NSCLC
    M.C. Garassino, C. Saura, S. Tolaney, et al. · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  100. Abstract 93012026-06-01 · 13:00 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-722 study)
    H. Borghaei, M.C. Garassino, S. Tolaney, et al. · Institut Gustave Roussy
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  101. Abstract 97592026-06-03 · 14:15 CT · S406
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-596
    S. Antonia, N. Rizvi, S. Modi, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  102. Abstract 92942026-06-01 · 19:15 CT · Hall B1
    KEYNOTE-533: Keytruda (pembrolizumab) adjuvant in NSCLC
    R. Herbst, M.C. Garassino, E. Winer · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  103. Abstract 90402026-06-04 · 19:30 CT · S406
    FLAURA-554: Tagrisso (osimertinib) neoadjuvant in NSCLC
    P. Schmid, R. Herbst · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  104. Abstract 91412026-06-05 · 16:30 CT · Hall B1
    Long-term follow-up of Imfinzi 2L for SCLC: PACIFIC-410
    T. Mok, S. Peters, P. Schmid, et al. · Institut Gustave Roussy
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  105. Abstract 98882026-06-03 · 15:45 CT · S406
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-575 study)
    F. Andre, J. Cortes, J. Brahmer, et al. · Stanford Cancer Institute
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  106. Abstract 97212026-06-01 · 13:30 CT · E450
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-490
    H. Rugo, C. Robert, S. Modi · Royal Marsden Hospital
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  107. Abstract 96982026-06-04 · 15:45 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-733 study)
    M. Krop, G. Curigliano, E. Winer, et al. · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  108. Abstract 93602026-06-02 · 20:15 CT · Arie Crown Theater
    DESTINY-Breast-425: Enhertu (trastuzumab deruxtecan) maintenance in NSCLC
    C. Robert, J. Brahmer · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  109. Abstract 91882026-06-03 · 21:00 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-543
    T. Mok, M. Krop, S. Tolaney · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  110. Abstract 92192026-06-04 · 13:45 CT · Hall B1
    IMpower-823: Tecentriq (atezolizumab) 3L+ in NSCLC
    S. Antonia, E. Winer, A. Spira, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  111. Abstract 93032026-06-05 · 14:30 CT · S100A
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-299 study)
    M.C. Garassino, T. Mok, P. Schmid, et al. · MD Anderson Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  112. Abstract 94672026-06-04 · 15:45 CT · Hall B1
    Quality of life outcomes with Tecentriq in patients with NSCLC
    T. Mok, S. Tolaney, M. Reck · Stanford Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  113. Abstract 93242026-06-02 · 14:15 CT · S406
    KEYNOTE-332: Keytruda (pembrolizumab) maintenance in NSCLC
    N. Rizvi, S. Modi · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  114. Abstract 98932026-06-04 · 18:45 CT · E450
    Long-term follow-up of Imfinzi 1L for NSCLC: PACIFIC-134
    T. Mok, E. Winer · University of Chicago
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  115. Abstract 92722026-06-02 · 16:45 CT · E450
    PACIFIC-596: Imfinzi (durvalumab) 2L in NSCLC
    R. Herbst, M.C. Garassino, N. Rizvi, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  116. Abstract 92912026-06-01 · 19:45 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-531
    S. Modi, P. Schmid · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  117. Abstract 91312026-06-01 · 14:00 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-936 study)
    M. Krop, T. Mok, E. Winer · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  118. Abstract 95252026-06-02 · 14:45 CT · E450
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-158
    F. Andre, C. Saura, T. Mok · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  119. Abstract 91782026-06-05 · 15:30 CT · S100A
    FLAURA-383: Tagrisso (osimertinib) 1L in NSCLC
    M.C. Garassino, N. Rizvi, J. Brahmer, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  120. Abstract 90492026-06-05 · 16:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-20 study)
    H. Borghaei, F. Andre, G. Curigliano · Princess Margaret Cancer Centre
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  121. Abstract 92242026-06-05 · 13:30 CT · E450
    PACIFIC-647: Imfinzi (durvalumab) maintenance in NSCLC
    S. Peters, M.C. Garassino, F. Andre, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  122. Abstract 91552026-06-03 · 20:30 CT · Arie Crown Theater
    KEYNOTE-588: Keytruda (pembrolizumab) 3L+ in SCLC
    C. Saura, M.C. Garassino · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  123. Abstract 94372026-06-03 · 21:00 CT · Hall B1
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-434
    M.C. Garassino, H. Rugo, R. Herbst · Institut Gustave Roussy
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  124. Abstract 99382026-06-02 · 20:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-958 study)
    H. Borghaei, S. Antonia · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  125. Abstract 95862026-06-02 · 15:45 CT · Hall B1
    Long-term follow-up of Opdivo 1L for NSCLC: CheckMate-35
    C. Saura, S. Modi · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.